On November 14, the China Resources Pharmaceutical (CR Pharma) was included in the MSCI (Morgan Stanley Capital International) China Index, effective on December 1, 2017. CR Pharma is also included in the Hang Seng China-Affiliated Corporations Index and the Hang Seng Mainland (Hong Kong Stock) Composite Index 100, effective from December 4, 2017.
As a key reference for institutional investors in global stock markets, MSCI includes companies with good business performance and high potential. The selected shares must meet the requirements of market value, volume and stock liquidity, for which MSCI is of high reference value. Before the inclusion, CR Pharma has been incorporated into a number of composite indexes, including Hang Seng Composite Large-Cap Index, Hang Seng Mainland Healthcare Index, Hang Seng Healthcare Index, FTSE All-World Index (Large Cap), FTSE Global Index and FTSE All-World Index. The inclusion of the MSCI China Index proved again the acknowledgement of capital market on the business development of CR Pharma.